RxDoctor Payments Data

Michael Hames, DPM

Podiatrist · Florence, ALNPI 1811058258

Payments from drug & device makers

What this record shows

This record is dominated by other: $98,200 of the $100,054 with a category attached, or 98.1%. Convatec Inc. accounts for 98.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $98,699, more than ten times the $16 reported in 2019. Among podiatrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,054in general payments, 2019–2025

Across 114 payments — averaging $877.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$98K
  • Stryker$641
  • Paratek Pharmaceuticals, Inc.$491
  • Melinta Therapeutics, LLC$153
  • Kowa Pharmaceuticals America, Inc.$140
  • Organogenesis Inc.$130
  • plus $255 from 9 others

What the payments were for

  • Food & beverage$1,8542%
  • Other$98,20098%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,054 in reported general payments places this provider in the 95th percentile of 59 podiatrist providers in Alabama.

See all podiatrist providers in Alabama

Medicare billing

Part B allowed, 2024
$359,648
Medicare patients
674
Services billed
3,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DalvanceDalbavancin Hcl77$445,723
NuzyraOmadacycline Tosylate21$110,026
Pregabalin286$5,983
SantylCollagenase Clostridium Hist.14$4,929
Meropenem13$2,625
Febuxostat29$2,132
Ciclopirox77$2,009
Gabapentin178$1,926
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen62$1,163
Nortriptyline Hcl113$1,087
Diclofenac Sodium30$857
Gentamicin Sulfate24$835
Terbinafine Hcl188$811
Doxycycline Hyclate141$803
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieDalvance$108$445,72377 claims
Paratek Pharmaceuticals, Inc.Nuzyra$491$110,02621 claims
Smith+NephewSantyl$13$4,92914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 59 podiatrist providers in Alabama.

Other podiatrist in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →